IFN-y produced by Tamp cells early after adoptive transfer are influential in the development of the amplified anticryptococcal DTH response that has been observed in Tamp cell-recipient mice.
Life-threatening disease caused by Cryptococcus neoformans has been increasing significantly in the United States and elsewhere in the world because of the increase in the numbers of immunosuppressed individuals as a result of AIDS and immunosuppressive drug therapy (6, 20, 23, 38) . One approach to treatment of cryptococcosis in immunocompromised individuals could be immunoreplacement or immunopotentiation therapy. However, development of appropriate immunotherapeutic protocols cannot be accomplished without a comprehensive understanding of the anticryptococcal host resistance mechanisms including the cells and cytokines involved in those mechanisms. Cell-mediated immunity (CMI) is a key host defense mechanism against C. neoformans (7, 31) ; therefore, this report is focused on defining the lymphokines associated with induction and regulation of the anticryptococcal CMI response.
With the murine model, several lymphocyte populations involved in the anticryptococcal CMI response measured by delayed-type hypersensitivity (DTH) have been identified and characterized to some degree (3, 9, 10, 25, 26, 31, 34 (18) . The other CD4+ cell population induced by immunization with CneF-CFA is a population that amplifies the anticryptococcal DTH resjonse (9, 10) . The latter cells are referred to as anticryptococcal Tamp cells (9, 10) . When (9) . In contrast, spleen cells from immunized mice treated with the solvent in which the CsA was prepared in place of CsA could transfer DTH and could induce an amplified anticryptococcal DTH response in recipient mice (9) .
The main purpose of the present study was to determine what cytokines are produced by spleen cells taken from mice during the development of anticryptococcal TDH and Tamp cells and to compare those cytokine profiles with cytokine profiles of similar cell populations from mice treated with CsA to inhibit the development of Tamp cells. Furthermore, the cytokines produced by the same spleen cell populations after in vitro stimulation with cryptococcal antigen were assessed. Since we know that transfer of immune spleen cells to mice at the time of immunization of the recipient mice results in a greatly amplified anticryptococcal DTH response in the recipient, the cytokines produced in vitro in response to cryptococcal antigen should shed light on the cytokines produced in the Tamp cell-recipient mice after stimulation with cryptococcal antigen. In other words, cytokine production by immune spleen cells in vitro in response to cryptococcal antigen would be somewhat analogous to the in vivo response during the early phase of induction of the amplified anticryptococcal DTH response.
The results of this study show that spleen cell populations which contain the TDH and Tamp cells produced more gamma interferon (IFN-y) and interleukin-2 (IL-2) than pools that contained only TDH Maintenance of endotoxin-free conditions. To prevent endotoxin from influencing the experimental results, all experiments were performed under conditions which minimize endotoxin contamination. This included the use of plastic ware that was endotoxin-free, glassware that had been heated for 3 h at 180°C, and reagents that had been found to contain less than 8 pg of endotoxin per ml (minimal detectable level) with the Limulus assay (Whittaker Bioproducts, Inc., Walkersville, Md.).
Antigen. CneF used for immunization, footpad challenge, and stimulation of lymphoid cells in vitro was prepared by the procedure described by Buchanan and Murphy (4) from C. neoformans 184-A (32). The lot of CneF used in these studies had a protein concentration of 95 pg/ml based on the BCA protein assay (Pierce, Rockford, Ill.) and a carbohydrate concentration of 4.2 mg/ml determined by the phenolsulfuric acid assay (8) . This lot of CneF gave a reaction with the Limulus test equivalent to 32 pg of endotoxin per ml; however, since CneF has a high concentration of glucuronoxylomannan and glucuronic acid that give positive reactions in the Limulus assay, the reactivity observed with the CneF in the Limulus assay was considered to be due to the glucuronic acid rather than to endotoxin contamination (lectins and lectin conjugates; EY Laboratories, Inc., San Mateo, Calif.) (35) .
Induction of TDH cells in CsA-treated mice and induction of TDH and Tamp cells in control mice. To induce anticryptococcal TDH cells in the absence of Tamp cells, mice were immunized with CneF-CFA at two sites at the base of the tail on day 0 and treated intramuscularly with CsA (60 mg/kg per day) dissolved in 30 F.l of solvent (Labrifil in 12.5% ethanol) every 24 h beginning on day -1 and continuing through day 5 (9) . Both anticryptococcal TDH and Tamp cells were induced by injecting CneF-CFA subcutaneously at two sites at the base of the tail into mice given the solvent without CsA by the same schedule and route that the CsA was given (9) .
Collection of spleen cells from CsA-and solvent-treated, immunized mice. At 1, 2, 4, and 6 days after immunization with CneF-CFA, spleens were removed from the mice and single-cell suspensions were made as described previously (33) .
In vitro culture of spleen cells for cytokine production. Spleen cells (5 Gaithersburg, Md.) . After being coated, the wells were washed with phosphate-buffered saline (pH 7.2) containing 0.05% Tween 20 (PBST) and blocked with PBST supplemented with 3% bovine serum albumin for 30 min at 37°C. The cell supernatants to be assessed for IFN--y were added to duplicate wells, and the plates were incubated for 2 h at room temperature. After the wells were washed, polyclonal rabbit anti-mouse-IFN--y serum (diluted 1:250) was added to each well, and the plates were incubated for 2 h at room temperature. The wells were washed with PBST, and donkey anti-rabbit IgG conjugated to horseradish peroxidase (Jackson Immunoresearch Laboratories, Inc., West Grove, Pa.) was added to each well. After a 1-h incubation at room temperature, the wells were washed before o-phenylenediamine (Sigma) was added. The color was allowed to develop for 5 min, and the A490 was read on a Microplate Reader (Dynatech, Chantilly, Va.). The amount of IFN-y was calculated from a standard curve and expressed as nanograms per milliliter. IFN-y purchased from Genzyme (Cambridge, Mass.) was used for the standards and the positive control. The assay detected as little as 0.125 and as much as 8.2 ng of IFN--y per ml. Neither IL-2 at 1.02 ng/ml, IL-4 at 1.43 ng/ml, IL-5 at 1.0 ng/ml, nor TNF at 25 ng/ml was detectable in the assay.
The IL-2 assay was performed in a manner similar to the IFN--y assay; however, the capture antibody used to coat the wells for the IL-2 assay was a rat anti-mouse-IL-2 IgG2a (PharMingen, San Diego, Calif.). The samples were incubated in the antibody-coated wells overnight at 4°C before washing and adding the secondary antibody, which was biotinylated rat anti-mouse-IL-2 IgG2b (PharMingen). After the secondary antibody was applied and unbound antibody was removed by washing, avidin D conjugated to horseradish peroxidase (Vector Laboratories, Burlingame, Calif.) was added to each well. After being incubated and washed, the plates were developed as described for the IFN--y en- IL-4 was measured in a manner similar to that used for IL-2 assessment; however, rat anti-mouse-IL-4 IgG2b (Phar Mingen) was the capture antibody, and the secondary anti- IL-5 concentrations were measured with a protocol similar to the one described for the IL-2 ELISA. For the IL-5 ELISA, the capture antibody used to coat the wells was a purified rat anti-mouse-IL-5 IgGl (PharMingen) and the secondary antibody was a biotinylated rat anti-mouse-IL-5 IgG2a (PharMingen). Recombinant mouse IL-5 obtained from PharMingen was used for the standards and the positive control. The minimal and maximal concentrations of IL-5 detectable with this assay were 25 and 500 pg/ml, respectively. Other cytokines, such as IL-2 (1.02 ng/ml), IL-4 (1.43 ng/ml), IFN-- (9) . In contrast, mice given the solvent in which the CsA was dissolved in place of the CsA (Sol treated) developed both TDH cells and Tamp cells in their spleens (9) . In the present study, mice were treated with CsA or Sol and immunized with CneF-CFA as in the earlier study, and their spleen cells were removed at 1, 2, 4, and 6 days after immunization. The spleen cells were cultured in tissue culture medium alone to determine constitutive cytokine production or with CneF to assess the ability of the cells to respond to cryptococcal antigen, with the T-cell IFN-y production by spleen cell populations containing anticryptococcal TDH and Tamp cells compared with production by cell populations containing only TDH cells. Spleen cells from Sol-treated, immunized mice cultured in vitro for 48 h produced low levels (0.33 ± 0.08 ng/ml) of IFN--y constitutively at the earliest time studied (1 day) after immunization ( Fig. 2A) . Under the same culture conditions, naive CBA/J spleen cells produced, on average, 0.17 ± 0.005 ng of IFN--y per ml, a level that was only slightly above the detectable level of the IFN-y ELISA (0.125 ng/ml). The amount of IFN--y constitutively produced by spleen cells from Soltreated, immunized mice was significantly higher than the levels of IFN-y produced by naive spleen cells (P = 0.035) or by spleen cells from CsA-treated mice at day 1 (P = 0.03). Constitutive production of IFN-y by spleen cells from Soltreated, immunized mice increased through day 4 after immunization, and then a level similar to the production level on day 4 was maintained at 6 days ( Fig. 2A ). Spleen cells removed from Sol-treated mice at 4 and 6 days after immunization produced significantly increased amounts of IFN--y in response to CneF compared with constitutive production (P < 0.01; Fig. 2A ). The peak in IFN--y production in response to CneF occurred at day 4 or 6 depending upon the experiment. In contrast, with a single exception, which was at the day-4 time period, the spleen cells from CsA-treated, immunized mice did not constitutively produce measurable levels of IFN--y that were significantly elevated above the levels produced by naive control cells incubated for 48 h in CTCM ( Fig. 2A) . Spleen cells taken from the CsA-treated mice 6 days after immunization could be stimulated with CneF to produce IFN--y in concentrations equivalent to the constitutive production by spleen cells from Sol-treated, immunized mice ( Fig. 2A) . In addition, the CneF-induced production of IFN-y by the cells removed 6 days after immunization from the CsA-treated animals was significantly greater than the constitutive production of IFN-y by those cells (P = 0.001; Fig. 2A ).
ConA-stimulated spleen cells from Sol-treated, immunized mice produced significantly more IFN-,y than did ConA-stimulated spleen cells from CsA-treated, immunized mice irrespective of the time after immunization that the spleen cells were removed from the mice (P < 0.01; Fig. 2B ).
This reduced production of IFN--y by spleen cells from CsA-treated mice was not due to diminished viability of the cells after incubation in ConA, because ConA-stimulated spleen cells from CsA-treated mice had the same viability as the ConA-treated spleen cells from Sol-treated mice (Fig.  1C) . The ability of the spleen cells from Sol-treated, immunized mice to respond to ConA with the production of IFN--y was greatest at 1 and 2 days after immunization and tended to diminish slightly thereafter (Fig. 2B) PMA-Ca2" ionophore stimulated naive mouse spleen cells to produce IFN--y, however, the amount produced (2.4 + 1.5 ng/ml) was much less than the amount produced by the same cells stimulated with ConA (36.5 + 7.6 ng/ml). Spleen cells from CsA-treated, immunized mice produced even lower amounts of IFN-y in response to PMA-Ca2+ ionophore (average of 0.71 ng/ml). In contrast, PMA-Ca2+ ionophorestimulated spleen cells from Sol-treated, immunized mice produced levels of IFN--y (2.6 ng/ml) equivalent to that of the naive control spleen cells but significantly higher than that of spleen cells from CsA-treated, immunized mice (P = 0.04), no matter which day after immunization the spleen cells were removed. There was a difference between the viability of the ConA-stimulated cells and that of the PMA-Ca2+ ionophore-stimulated cells (Fig. 1C and D (Fig. 3A) , CneF did not appear to influence production (0.031 ± 0.004 ng of IL-2 per ml for the CneFstimulated cells). In contrast, the constitutive production of IL-2 by spleen cells removed 4 days after CsA treatment and immunization (0.015 ± 0.006 ng/ml) was comparable to the production by naive spleen cells (0.017 ± 0.006 ng of IL-2 per ml) or to production by spleen cells removed at day 1 or 2 from CsA-treated immunized mice and cultured in medium alone or with CneF (0.007 ± 0.003 ng/ml). Cells at day 4 were stimulated by CneF to produce slightly but not significantly more IL-2 (0.025 ± 0.006 ng of IL-2 per ml). By day 6 after immunization, neither the spleen cells from the Sol-treated animals nor those from CsA-treated animals constitutively produced more IL-2 than did the spleen cells from naive mice, but when the spleen cells from Sol-treated, immunized mice were stimulated with CneF, more than three times as much IL-2 was produced than was produced by spleen cells removed 6 days after immunization of the CsA-treated mice (Fig. 3A , compare 0.089 ± 0.015 to 0.029 ± 0.005 ng/ml; P < 0.0001). Spleen cells taken from the CsA treatment group at 6 days after immunization produced significantly more IL-2 after stimulation with CneF than they produced constitutively (compare 0.029 ± 0.005 to 0.009 ± 0.002 ng/ml; P = 0.004).
The spleen cells from Sol-or CsA-treated, immunized mice produced IL-2 in response to both ConA (Fig. 3B) and PMA-Ca2+ ionophore (data not shown). ConA stimulation generally resulted in more IL-2 production than did stimulation with PMA-Ca2+ ionophore. CsA treatment of mice slightly reduced, on occasion, the IL-2 production by spleen cells in response to ConA, as was seen for spleen cells removed at 4 and 6 days (Fig. 3B) or in response to PMA-Ca2" ionophore (data not shown); however, the reductions in IL-2 production were not significant nor reproducible in replica experiments. Although CsA is reported to inhibit IL-2 production (21), spleen cells removed from mice treated with CsA and put into culture without CsA responded to strong stimuli such as ConA and PMA-Ca2+ ionophore with the production of IL-2, generally at levels equivalent to those produced by naive spleen cells stimulated with the same reagent(s).
IL-4 and IL-5 production by spleen cells from CsA-or (Fig. 4B) . IL-5 production in response to ConA by spleen cells from Sol-or CsA-treated, immunized mice was similar for the two groups (Fig. SB) . In the experiment shown in Fig. 5B , the production of IL-5 in response to ConA was highly variable on days 2 and 4 after immuniza- tion. The differences seen between the Sol-and CsA-treated groups at days 2 and 4 were not consistent findings in replica experiments and therefore were considered to result from some unknown variable in this one experiment.
Production of TNF by spleen cells from CsA-or Sol-treated mice immunized with CneF-CFA. TNF was not constitutively produced nor was it produced after stimulation with CneF by spleen cells from CsA-or Sol-treated, immunized mice (Fig.  6A ). The TNF ELISA was shown to be reliable for the detection of TNF in supernatants from spleen cells by the fact that TNF was detected in 48-h supernatants from PMA-Ca2+ ionophore-stimulated spleen cells from Soltreated, immunized mice (Fig. 6B) . Naive spleen cells from CBA/J mice produced, on average, 0.27 ng of TNF per ml after being cultured for 48 h with PMA-Ca2" ionophore, and that level of TNF production was similar to the production of TNF by spleen cells at day 1 or 2 after immunization of Sol-treated mice (Fig. 6B) . By 4 and 6 days after immunization, the spleen cells of the Sol-treated mice displayed reduced production of TNF in response to PMA-Ca + ionophore (Fig. 6B) . CsA treatment of mice abrogated the ability of the spleen cells to respond to PMA-Ca2+ ionophore with the production of TNF (Fig. 6B) .
DISCUSSION
On the basis of data from other antigen models, it is generally accepted that the lymphokines produced during the induction of an immune response influence the types of mature antigen-reactive lymphocytes that develop (2, 27) . For example, if antigens stimulate the production of IFN--y, then there is a preferential induction of Thl cells and Th2 cells are suppressed (12) . Likewise, if IL-4, a Th2-associated lymphokine, is produced, the induction of Th2 cells is favored and the induction of Thl cells is inhibited (36) . The lymphokines produced during the induction of an anticryptococcal immune response have not been elucidated previously; however, on the basis of findings in other antigen models in which DTH is the major immune response, it could be anticipated that Thl-associated lymphokines (IL-2 and IFN-y) would be the predominant ones produced. The data presented here clearly demonstrate that this is the case, since IL-2 and IFN--y, but not IL-4 and IL-5, were produced by the spleen cells from CneF-immunized mice.
Induction of Tamp cells but not TDH cells can be inhibited by treating mice with CsA during the induction period of the two populations of anticryptococcal responsive T cells (9) . Since CsA has been shown to depress the production of a number of lymphokines (37) (9) , and at 4 days after immunization of those mice, IFN--y is not produced in amounts significantly above background levels for naive mice. IL-2 was consistently produced at higher levels in the mice in which both Tamp and TDH cells were developing than in mice in which only TDH cells were maturing. The constitutive production of IL-2 at 4 days was clearly different between the cells from the Sol-and CsA-treated, immunized mice, but the difference in the IL-2 levels between CneF-stimulated spleen cells from the Sol-and CsA-treated mice at 4 days after immunization was not always significant. IL-2, like IFN-y, may be important in the maturation of the Tamp cells, but the differences in IL-2 levels are more difficult to demonstrate because the maturing, proliferating cells are using the IL-2 as it is being produced and the levels being measured reflect only the unused portion of IL-2 at the time of assessment. The more IL-2 receptor-positive cells in a population, the more activated cells there are and thus more IL-2 will be used. It stands to reason, then, that the spleen cells from Sol-treated, immunized mice containing both anticryptococcal TDH and Tamp cells would produce and use more IL-2 than spleen cells from CsA-treated, immunized mice that have only TDH cells. IL-4, IL-5, and TNF do not appear to have a role in the development of the anticryptococcal TDH or the Tamp cells because measurable levels of these cytokines were not produced by spleen cells from mice immunized with cryptococcal antigen. Although it seems remote, it is possible, however, that levels of IL-4 below 6.25 pg/ml or of IL-5 below 25 pg/ml (minimal detectable levels) could be affecting the induction of the anticryptococcal sensitized T cells. This possibility cannot be ruled out on the basis of the data presented here.
Since the anticryptococcal TDH cells are produced in the spleens of immunized mice by 4 days after immunization (30) , the lymphokines present at days 1 and 2 after immunization would be expected to be the most influential in the maturation process of the TDH cells. Of the cytokines measured, IL-2 was the only cytokine produced at days 1 and 2 by spleen cells from CsA-treated, immunized mice.
Considering that some CneF from the immunizing injection of CneF-CFA would still be present in the mouse system throughout most, if not all, of the 6-day period after immunization, the anticryptococcal TDH cells may be developing in an environment more equivalent to the experimental conditions in which the spleen cells were stimulated with CneF. If this is the case, the data suggest that an environment in which there are minimal concentrations of IL-2 and IFN-y is satisfactory for the development of anticryptococcal TDH cells. The inability to measure IL-4, IL-5, or TNF from spleen cell supematants indicates that these three cytokines are not likely to be involved in the development of the anticryptococcal DTH response.
Finding IL-2 at low but measurable levels in supernatants fromCsA-treated, immunized mouse spleen cells may at first glance appear to be challenging the current dogma thatCsA blocks the production of lymphokines such as IL-2 and IFN--y (37). It could be argued that the IL-2 produced by spleen cells in culture for 24 h in the absence of CsA does not necessarily reflect what is occurring in the spleens ofCsAtreated mice, especially in the spleens of mice at 1, 2, or 4 days after immunization, becauseCsA was administered to the mice during that period on a daily basis. This is clearly a valid argument and must be considered. In addition, T-cell maturation and expansion into a population of antigenspecific T cells require IL-2 along with the appropriate presentation of antigen on antigen-presenting cells (22) . Therefore, if low levels of IL-2 are not produced in the spleens of mice undergoing the induction of an anticryptococcal CMI response, then how can anticryptococcal TDH cells be induced and expanded? Conclusions from recent studies onCsA action may help resolve these seemingly contradictory results. CsA has been shown to affect calciumassociated signaling events involved in the regulation of lymphokine gene expression; however, pathways that signal through CD28 are resistant toCsA (17) . Stimulation of T cells to differentiate and proliferate requires two signals (29) ; the first signal is via the specific antigen-major histocompatibility complex interaction with the T-cell receptor, and the second could be through another receptor such as CD28 on (14) . In the latter study, cytokine profiles were similar whether specific antigen or ConA was used as a stimulant (14) . With the exception of the IFN--y production to ConA, the cytokine levels after anticryptococcal sensitized spleen cells were stimulated with ConA were similar to the cytokine levels produced when naive spleen cells were stimulated with ConA. In the case of the IFN--y production to ConA, the spleen cells at 1 and 2 days after immunization with CneF-CFA produced more IFN-,y in response to ConA than naive controls. This increase in productivity of IFN--y cannot be attributed to better viability of the spleen cell populations from the immunized mice. Several possible reasons can be offered to explain the increased production of IFN--y in response to ConA by spleen cells removed early after immunization. First, it is possible that CneF-CFA injection results in an early increase in the numbers of cells responsive to ConA. Second, the immunization may stimulate accessory cells to have enhanced abilities to participate in the ConA-induced lymphokine production. Third, the immunization may increase the capacity of the responsive cells to produce IFN--y when stimulated with a strong stimulant such as ConA. TNF has been shown to be induced by a number of microbial agents and their antigens (1); therefore, it was expected that CneF would induce the spleen cells to produce TNF. However, that was not the case. Neither naive nor CneF-sensitized spleen cells produced TNF in response to CneF. The cells were capable of producing TNF when appropriately stimulated; therefore, their lack of response to CneF with TNF production indicates that CneF does not induce murine spleen cells to produce TNF and that CneF is not contaminated with sufficient amounts of endotoxin to induce TNF production. The lower viability of the cells cultured in medium with PMA-Ca2+ ionophore compared with that of cells cultured in medium alone or with CneF or ConA could have resulted in part from the greater production of TNF by PMA-Ca2+ ionophore-stimulated cells because TNF is known to be cytotoxic (24) . However, TNF differences between spleen cells from CsA-and Sol-treated, immunized mice did not parallel the viability differences between the two spleen cell populations; therefore, it is unlikely that reduced TNF production by spleen cells from CsA-treated mice can be attributed to reduced numbers of 
